The duration of CAR T-cells’ presence in the body varies from patient to patient and depends on multiple factors. Typically, infused CAR T-cells can persist in the body for months to years after treatment. However, their persistence may decline over time. Despite this, some CAR T-cells may remain in the body as memory T-cells, providing […]

Yes, CAR T-cells can proliferate in the body. After infusion into the patient, CAR T-cells continue to multiply and expand in numbers, creating a strong and sustained immune response against the targeted cancer cells. This proliferation is essential for the CAR T-cells to effectively locate and destroy cancer cells throughout the body. However, excessive proliferation […]

Yes, CAR T-cells used in CAR T-cell therapy are typically autologous, meaning they are derived from the patient’s own immune cells. During the treatment process, T-cells are collected from the patient through leukapheresis, genetically engineered to express chimeric antigen receptors (CARs) and then infused back into the patient’s body. Using autologous CAR T-cells reduces the […]

After CAR T-cell therapy, patients can experience a range of responses. Some may achieve complete remission or significant disease reduction, leading to improved outcomes. However, there can also be side effects like cytokine release syndrome (CRS) or neurotoxicity, which require careful monitoring and management. Regular follow-up visits and assessments are essential to track treatment response […]

CAR T-cell therapy has shown great promise in the treatment of multiple myeloma, a type of blood cancer affecting plasma cells. In this therapy, T-cells are extracted from the patient and genetically engineered to express chimeric antigen receptors (CARs) targeting the B-cell maturation antigen (BCMA), a protein commonly found on myeloma cells. After CAR modification, […]

The duration of CAR T-cell therapy can vary from patient to patient and depends on several factors, including the type of cancer being treated and the individual’s response to the treatment. Generally, the entire process can take a few weeks to complete. This includes the time required for leukapheresis to collect T-cells, the modification of […]

No, hair loss is not a common side effect of CAR T-cell therapy. Unlike traditional chemotherapy, which often causes hair loss due to its impact on rapidly dividing cells, CAR T-cell therapy targets cancer cells differently. During CAR T-cell therapy, the patient’s own T-cells are genetically modified to express chimeric antigen receptors (CARs) that target […]